Furathiocarb
Based on 1 Customer Validation
Furathiocarb is a carbamate pro-insecticide and a contact allergen. Furathiocarb is commonly used in studies related to contact allergy. Furathiocarb induces significant proliferation of MHC II-positive B cells in auricular lymph node cells and induces the production of Th1 cytokines (such as IL-2, TNF-γ and IFN-γ). However, Furathiocarb does not induce respiratory allergy in mice. After absorption through the abdominal skin of isolated rats, Furathiocarb is completely metabolized into carbofuran, and its permeation amount increases with time and dosage. The skin permeation rates of both emulsifiable concentrate (EC) and wettable powder (WP) formulations of Furathiocarb are higher than that of Furathiocarb itself, with no significant difference between the two formulations.
For research use only. We do not sell to patients.
- Purity : 99.21%
- CAS No.: 65907-30-4
- Formula: C18H26N2O5S
- Molecular Weight:382.48
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
In Vivo
After long-term skin sensitization and intratracheal challenge in female BALB/c mice with Furathiocarb (1% for sensitization, 0.01-0.1% for challenge; sensitization is administered topically, challenge is administered intratracheally; sensitization is performed on days 1-3, 8-10, and 15-17, with a single challenge dose given on day 31), no significant Th2 activation is observed in lung-associated lymph nodes, and no respiratory allergen immune characteristics are induced[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice with Allergic contact dermatitis (female, 7 weeks old)[1]
-
Dosage:1% (sensitization); 0.01% (challenge), 0.1% (challenge)
-
Administration:topical; on days 1-3, 8-10, 15-17 (sensitization); topical; single dose on day 31 (challenge)
-
Result:Did not cause statistically significant increases in total serum IgE levels in any furathiocarb-treated groups relative to controls.
Caused statistically significant increases in total lymphocyte counts, MHC Class II-positive B-cell counts, and IgE-positive B-cell counts in auricular lymph nodes at 0.1% challenge dose (after 1% sensitization) relative to control groups.
Caused IgE-positive B-cell counts to be significantly higher than in the low-dose challenge group at 0.1% challenge dose (after 1% sensitization).
Caused statistically significant increases in total lymphocyte counts and MHC Class II-positive B-cell counts in auricular lymph nodes at 0.01% challenge dose (after 1% sensitization) relative to non-sensitized controls.
Induced statistically significant increases in Th1 cytokines (IL-2, TNF-α, IFN-γ) and Th2 cytokines (IL-4, IL-5, IL-10, IL-13) in ex situ culture of auricular lymph node cells relative to controls, though Th2 cytokine responses were milder than those induced by 2,4-D.
-
Animal Model:BALB/c mice with Respiratory allergy (female, 7 weeks old)[1]
-
Dosage:1% (sensitization); 0.01% (challenge), 0.1% (challenge)
-
Administration:topical; on days 1-3, 8-10, 15-17 (sensitization); intratracheal; single dose on day 31 (challenge)
-
Result:Did not cause statistically significant increases in total IgE levels in serum or BALF in any furathiocarb-treated groups relative to controls.
Did not cause elevations in total or differential cell counts (eosinophils, neutrophils, macrophages) in BALF, aside from a mild, statistically significant increase in MIP-1β levels in the high-dose challenge group relative to controls.
Did not cause statistically significant increases in IgE-positive B-cell or MHC Class II-positive B-cell counts in lung-associated lymph nodes.
Did not induce statistically significant increases in Th2 cytokines (IL-4, IL-10, IL-13) in ex situ culture of lung-associated lymph node cells relative to controls.
Chemical Information
-
CAS No. 65907-30-4
-
Appearance Oil
-
Molecular Weight 382.48
-
Formula C18H26N2O5S
-
Color Colorless to light yellow
-
SMILES
O=C(OC1=CC=CC2=C1OC(C)(C)C2)N(SN(C(=O)OCCCC)C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (731 KB)
- English - EN (731 KB)
- Français - FR (731 KB)
- Deutsch - DE (731 KB)
- Norwegian - NO (731 KB)
- Español - ES (731 KB)
- Swedish - SV (731 KB)
- Italian - IT (731 KB)
- Korean - KR (731 KB)
- Portuguese - PT (731 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)